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proves representative, the proposed approach may effi-
ciently target secondary PP1 partners with high-affinity
RVxF instances. Interestingly, given that the number of
primary PP1 partners has stagnated in recent years,
secondary interactors show the highest potential for
growth via novel discovery approaches like the one pro-
posed by Meiselbach and coworkers. Other recently de-
scribed PP1 binding motifs [12–14] may inspire addi-
tional strategies.
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for Chemokine Receptors
Chemokine receptors have attracted a good deal of
public attention as important therapeutic targets for
many diseases and disorders. In this issue of Chemis-
try & Biology, Kumar and colleagues propose a new
concept of synthetic modular modifications to gener-
ate unnatural chemokines, which exhibit high receptor
selectivity [1].
In a postgenome and proteome era, selective agonists
and antagonists can be highly useful for studies of re-
ceptor biology and for clinical applications. Chemokines
belong to a chemotactic cytokine family that attracts
and induces migration of leukocytes. Chemokines and
their receptors play fundamental roles in physiological
phenomena. Since these actions are relevant to many
pathological disorders such as cancer and AIDS, che-
mokine receptors are thought to be critical drug targets.
Chemokine receptors are members of the seven-
transmembraneGprotein-coupledreceptor (GPCR) fam-
ily, which transduce signals of corresponding chemo-
kines. The relationships between chemokines and their
receptors are highly interconnected and complicated:
a single chemokine recognizes a plurality of receptors,
while one chemokine receptor recognizes several che-
mokines. Numerous chemokines lack receptor selectiv-
ity. Unnatural chemokines that have high receptor selec-tivity would be practically useful, not only as specific
molecular probes for biological studies, but also as
drug leads for clinical application. Furthermore, the de-
velopment of systematic strategies to synthesize such
unnatural ligands would be desirable.
In this issue of Chemistry & Biology, Kumar and col-
leagues report unnatural synthetic molecules as chemi-
cal probes of chemokine receptors. They present the
concept of modular modifications to generate unnatural
chemokines that possess receptor selectivity [1]. They
created synthetically and modularly modified (SMM)-
chemokines based on a combination of total chemical
synthesis and modular modification. They chose
CXCR4 [2] and CCR5 [3–7] as target receptors with the
aim of potentially developing anti-AIDS drugs, since
these are the two principal coreceptors that are required
for HIV-1 entry. In addition to HIV infection/AIDS, CXCR4
has also been shown to be involved in several problem-
atic diseases, such as cancer metastasis [8, 9], leukemia
[10, 11], and rheumatoid arthritis [12, 13]. As such,
CXCR4 represents one of the greatest therapeutic tar-
gets for the above diseases. Although natural chemo-
kines for CXCR4 and CCR5 can inhibit HIV infection by
blocking gp120 binding regions on CXCR4 and CCR5,
respectively, serious problems remain concerning se-
lectivity, side effects, and toxicity profiles. vMIP-II,
which recognizes various chemokine receptors, was
chosen among chemokine ligands as the parent mole-
cule for modification [14]. For a detailed discussion of
CXCR4/CCR5 antagonists, readers are referred to re-
cent reviews [15, 16].
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9Figure 1. Development of Selective Ligands
for CXCR4 or CCR5 through Synthetic Modu-
lar Modifications Starting from a Native Che-
mokine, vMIP-II
Addition of the D-amino acid sequence de-
rived from the N-terminal region (1–10) of
vMIP-II to the N terminus of vMIP-II (11–71)
led to the development of a new molecule
with increased selectivity for CXCR4. Alterna-
tively, addition of the N-terminal (1–10) se-
quence of MIP-Ib, which is a foreign chemo-
kine specific for CCR5, to the N-terminus of
vMIP-II (11–71) resulted in the development
of a CCR5-selective ligand.Since knockout mice lacking CXCR4 are not viable,
the development of new modified ligands that interfere
only with HIV-1, but not with SDF-1a (the endogenous li-
gand) binding on CXCR4, would be ideal. The authors
and others previously reported that the N terminus of
SDF-1a and vMIP-II is important for CXCR4 binding
[17, 18] and that D-amino acid peptides derived from
the N-terminal (1–10) sequence of vMIP-II show high
binding selectivity for CXCR4 over CCR5 [19]. Thus,
the D-amino acid sequence was added to the N terminus
of vMIP-II (11–71) to develop RCP168, a new analog with
increased selectivity for CXCR4 (Figure 1). RCP168 does
not show agonistic activity or interfere with the physio-
logical action induced by SDF-1a (Ca2+ mobilization)
[1]. However, RCP168 shows potent anti-HIV activity
based on inhibition of HIV-1 entry through CXCR4. The
RCP168 binding region on CXCR4 overlaps that of
HIV-1 gp120, but not that of SDF-1a.
The authors also designed CCR5-specific SMM-
chemokines [1]. In this case, they utilized a ‘‘foreign N
terminus’’ in order to introduce differential receptor
binding (Figure 1). In essence, the N-terminal (1–10) se-
quence of MIP-Ib, which is a CCR5-specific chemokine,
was adopted. The resulting molecule, which is desig-
nated as RCP188, proved to be selective for CCR5.
However, RCP188 shows agonistic activity and inter-
feres with Ca2+ mobilization induced by MIP-1b, which
is in a sharp contrast to the CXCR4-specific SMM-
chemokine, RCP168.
Since GPCRs, such as chemokine receptors, are great
targets for drug discovery and chemical biology, spe-
cific molecular probes are highly useful for character-
izing biological functions of receptors. In this regard,
the authors’ objective to produce specific ligands is to
be commended. The present results provide highly use-
ful insights for the future design of synthetic chemokine
ligands. These selective chemokines could become in
great demand by receptor biologists and pharmacolo-
gists. Certainly, RCP168 has promise as a lead for
anti-AIDS/HIV drugs. Although Huang and coworkers
developed SMM-chemokines, which are specific li-
gands for CXCR4 or CCR5, it is unclear as to the gener-
ality of their strategy. It is ambiguous how one designs
ligands that are specific for target receptors, or ligands
that do or do not interfere with the physiological actions
induced by endogenous ligands. In practice, one might
design ligand molecules on a case-by-case basis
through trial and error to develop selective ligands.
However, it may be challenging to establish a more gen-eral concept for molecular design. In the era of chemical
biology, there is a great need for targeted molecules, in-
cluding biological probes to elucidate complicated pro-
teome networks. As a consequence, this field of re-
search will be dramatically developed in future.
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